UPDATE: Credit Suisse Initiates Genomic Health at Outperform on Growth Potential

Credit Suisse initiated coverage on Genomic Health

with an Outperform rating and a $43 price target. Credit Suisse said, "Genomic Health's stock has steadily appreciated over the past two years due to the success of its Oncotype DX cancer assays. We believe that the trend should continue as the company captures incremental market share with its already-established tests in breast and colon cancer and launches tests in new markets such as prostate cancer." Genomic Health closed at $36.15 on Monday.